References
- Rodvold KA. Pharmacokinetic and pharmacodynamic considerations for antimicrobial use. Infect Med 1995;12:16–25A
- Nightingale CH, Belliveau PP, Quintiliani R. Cost issues and considerations when choosing antimicrobial agents. Infect Dis Clin Pract 1995; 273:214–9
- Quintiliani R, Nightingale CH, Freeman CD. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection, with particular attention to oral cephalosporins. Infect Dis Clin Pract 1994; 3:1–7
- Conly JM, Low DE. Intravenous to oral antimicrobial stepdown therapy: improving the quality of care and reducing costs. Can J Infect Dis 1995; 6:3–5A
- Quintiliani R, Nightingale CH. Transitional antibiotic therapy. Infect Dis Clin Pract 1994; 3(3):S161–7
- Jewesson PT. Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy. Can J Infect Dis 1995; 6:11–6A
- Ballow CH. Cost considerations in oral antibiotic therapy. Adv Ther 1995; 12(4):199–206
- Vogel F. Transitional parenteral-to-oral therapy in community- acquired pneumonia. Hosp Pract 1996; 31:21–6
- Cunha BA. Community-acquired pneumonia: cost-effective antimicrobial therapy. Postgrad Med 1996; 99(1):109–10, 113–4, 117–9
- Degelau J, Guay D, Straub K, et al. Effectiveness of oral antibiotic treatment in nursing home-acquired pneumonia. J Am Geriatr Soc 1995; 43(3):245–51
- Zuck P, Rio Y, Ichou F. Efficacy and tolerance of Cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 1990; 26(Suppl E):71–7
- Gleckman RA. Oral empirical treatment of pneumonia: the challenge of choosing the best agent. Postgrad Med 1994; 95(2): 165–72
- Pneumonia Study Group. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob Agents Chemother 1996; 40(5):1175–9